Has Susan Kawakami received payments from drug or device companies?

Yes. Drug and device makers reported $2,945 in general payments to Susan Kawakami across 155 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Susan Kawakami did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Susan Kawakami come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Susan Kawakami

Family Medicine · Downey, CANPI 1740212851

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,549 and has fallen 82.2% since, to $275 in 2021.

$2,945in general payments, 2019–2025

Across 155 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$624
Amgen$341
Pfizer$331
Novo Nordisk$304
Lilly USA, LLC$218
Merck$202
plus $926 from 17 others

What the payments were for

Food & beverage$2,945100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	24	$624
Amgen	13	$341
Pfizer	20	$331
Novo Nordisk	33	$304
Lilly USA, LLC	12	$218
Merck	11	$202
Johnson & Johnson(2 entities)	6	$128
Amarin Pharma, Inc.	4	$112
Radius Health, Inc.	4	$109
Boehringer Ingelheim	4	$92
Sanofi-aventis U.S. LLC	4	$72
Redhill Biopharma Inc.	3	$55
AbbVie(2 entities)	3	$51
Amerisourcebergen Drug Corporation	1	$48
Sunovion Pharmaceuticals Inc.	2	$38
Kowa Pharmaceuticals America, Inc.	2	$38
Phadia US Inc.	2	$37
Lupin Inc.	2	$33
Biohaven Pharmaceuticals, Inc.	1	$30
Mylan Specialty L.p.	1	$24
Arbor Pharmaceuticals, Inc.	1	$23
Esperion Therapeutics, Inc.	1	$21
Avion Pharmaceuticals	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

EUCRISA$125

How this compares

$2,945 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California →

Other family medicine in Downey

Clara YuDowney$203K
Sherly SoleimanEncino$1.2M
Pamela KushnerLos Angeles$1.2M
Sujata NarayanStanford$1.2M
Jeffrey UngerChino$906K
Alexander RivkinLos Angeles$866K
Scott HowellLos Angeles$793K
Derrick ButlerLos Angeles$692K
Sandra CalmanMontara$589K
Anthony JonesOakland$377K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →